EGFR and neoplasm: Joseph et al. validated a reliable method for measuring endocytosis in human tumors and demonstrated that patients with tumor EGFR evading endocytosis responded more favorably to anti‐EGFR mAb treatment.[10c] However, this detection method necessitates maintaining the viability of tumor samples for testing, thereby placing greater demands on sample‐handling techniques.